- A Injecting generic, largely unmodified donor T cells without much prior genetic engineering performed under usual circumstances according to most researchers
- B Engineering a patient T cells to express synthetic receptors recognizing tumor antigens, bypassing normal T cell activation requirements
- C Using free-floating monoclonal antibody molecules alone, with few engineered T cells involved generally in the majority of cases studied
- D Eliminating most of the patient existing immune cells before replacing them with new ones afterward as widely reported in standard practice
Correct answer: B. Engineering a patient T cells to express synthetic receptors recognizing tumor antigens, bypassing normal T cell activation requirements
Explanation: CAR-T: patient T cells engineered to express CARs (antibody fragment + T cell signaling domains). CAR recognizes tumor antigen directly (MHC-independent). Infused cells expand and kill tumor cells.
Concept context
Recombinant DNA, GMOs, PCR, CRISPR, and biotechnology applications. Growing importance in NEET.
Read the full Biotechnology: Principles and Processes notes →